Theriva Biologics, Inc. · AMEX:TOVX
Theriva Biologics — Investor Presentation (December 2024)
42 slides from Theriva Biologics's investor presentation, December 2024
Slide 1: Corporate Overview December 2024
Corporate Overview December 2024
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward- looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "antici
Slide 3: Overview
OVERVIEW • Theriva Biologics is developing unique oncolytic viruses optimized for systemic administration Financial Snapshot Exchange NYSE American • VCN-01 is undergoing a Phase 2b clinical trial in Ticker TOVX first-line metastatic pancreatic cancer in Cash (09/30/2024) $16.4M combination with SoC
Slide 4: Seasoned Leadership Team
SEASONED LEADERSHIP TEAM Steven Shallcross Manel Cascalló PhD Vince Wacher PhD Chief Executive Officer, Chief Financial General Director, EU Subsidiary Head Corporate Development Officer Expertise in oncolytic adenovirus clinical Nearly 30 years leading corporate strategy, Served as the Company’s CE
Slide 5: Theriva Pipeline
THERIVA PIPELINE Candidate Target Pre-IND Phase 1 Phase 2 Phase 3 Collaborators Status* Phase 2b Study On-going Pancreatic Cancer (IV) with Orphan Drug Designation US, EU gemcitabine/nab-paclitaxel Fast Track Designation US Phase 1 Complete, CSR in preparation Retinoblastoma (IVit) Orphan Drug Desig
Slide 6: VCN-01 Is a Uniquely Engineered Human Adenovirus
VCN-01 IS A UNIQUELY ENGINEERED HUMAN ADENOVIRUS 5 Access primary and metastatic lesions Systemic High dose, highly replicating Replicates only in tumor cells Selective Liver detargeted Expresses PH20 (hyaluronidase) Stroma Degrading after viral replication cycle -- RGDK PH20 in blood is a potential
Slide 7: VCN-01 Is a Uniquely Engineered Human Adenovirus
VCN-01 IS A UNIQUELY ENGINEERED HUMAN ADENOVIRUS 5 SYSTEMIC administration enables VCN-01 access to SELECTIVE replication at very high levels lyses tumor 1 primary tumor and metastases and detargets the liver 2 cells directly without harming healthy tissues VCN-01 Tumor Surrounded by STROMA Cancer A
Slide 8: VCN-01 Designed to Have Multiple Anti-Tumor Actions
VCN-01 DESIGNED TO HAVE MULTIPLE ANTI-TUMOR ACTIONS STROMA degradation by PH20 facilitates tumor access IMMUNOGENIC actions of VCN-01 turn “cold” tumors 3 and destruction by coadministered cancer therapies 4 “hot” and elicit an anti-tumor immune response PH20 nab-paclitaxel PH20 PH20 PH20 gemcitabin
Slide 9: VCN-01 Compared to Other Oncolytic Viruses in Development
VCN-01 COMPARED TO OTHER ONCOLYTIC VIRUSES IN DEVELOPMENT THERIVA ONCOLYTICS COMPANY CG ONCOLOGY GENELUX REPLIMMUNE BIOLOGICS BIOTECH Ticker NYSE MKT: TOVX NASDAQ: CGON NASDAQ: GNLX NASDAQ:ONCY NASDAQ: REPL Market Cap¹ $3.5M $2.3B $86M $74M $984M Product VCN-01 CG0070 Olvi-Vec Pelareorep RP1, RP2 Vi
Slide 10: VCN-01 Extensive Clinical Program
VCN-01 EXTENSIVE CLINICAL PROGRAM 142 patients treated with VCN-01 to date in multiple indications and combinations Rb – IVit BRAIN TUMORS – IV (1)* alone (9) COLORECTAL – IV Alone (15) HEAD & NECK – IV alone (1) HEAD & NECK – IV PANCREATIC - IV + Durvalumab (20) + Gemcitabine / Abraxane® Phase 1 (2
Slide 11: VCN-01 Lead Indication Pancreatic Cancer
VCN-01 LEAD INDICATION PANCREATIC CANCER Highly fatal cancer protected by dense tumor stroma • Orphan disease with the highest mortality of all solid tumors • Median survival 8-11 months for metastatic disease1,2 • USA est. 66,440 new cases and 51,750 deaths in 20243 • Hyaluronic acid in stroma is a
Slide 12: VCN-01 Dose Regimen Established in Phase 1
VCN-01 DOSE REGIMEN ESTABLISHED IN PHASE 1 Multicenter, open-label, dose escalation study (NCT02045602) ✓ Single IV doses of VCN-01 alone or with standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel (Abraxane®) ✓ Evaluate safety and tolerability, recommended Phase 2 dose ¹Single dose of VC
Slide 13: VCN-01 Favorable Outcomes in Phase 1 Trial
VCN-01 FAVORABLE OUTCOMES IN PHASE 1 TRIAL Multicenter, open-label, dose escalation study (NCT02045602) OUTCOME VCN-01 DOSE, virus particles (n)¹ SoC ALONE² RELATED AEs IN ≥1 PATIENT¹ CTCAE SEVERITY Sequential Regimen 3.3x10¹² (6) 1.0x10¹³ (6) Combined (12) Phase 3 (431) VCN-01 Combined, Sequential
Slide 14: Clinical Data Support VCN-01 Mode-of-Action
CLINICAL DATA SUPPORT VCN-01 MODE-OF-ACTION Remodels the tumor matrix and turns “cold” tumors “hot” Persistent replication: PH20 levels in patient sera Immune markers upregulated in indicate sustained VCN-01 activity in tumors biopsies of hepatic metastases VCN-01 1.0x10¹³ vp (Arms I, II, III) CD8+
Slide 15: VIRAGE Phase 2b Clinical Trial in Pancreatic Cancer
VIRAGE PHASE 2B CLINICAL TRIAL in PANCREATIC CANCER Multicenter, open-label, randomized, controlled trial (NCT05673811) • Evaluating first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) • Randomized 1:1 to receive gemcitabine/nab-paclitaxel SoC or up to two doses
Slide 16: VIRAGE Phase 2 Clinical Trial Differentiators
VIRAGE PHASE 2 CLINICAL TRIAL DIFFERENTIATORS ✓ First-line treatment provides best opportunity to observe potential effect ✓ Direct comparison with SoC chemotherapy is the most rigorous control ✓ Repeated dosing of VCN-01 may improve treatment outcomes ✓ Open label provides real-time opportunity to
Slide 17: Achievements and Projected Milestones
ACHIEVEMENTS AND PROJECTED MILESTONES • VCN-01 PDAC • VCN-01 PDAC • VCN-01 PDAC • VCN-01 PDAC • Ph2 enrollment achieved ✓ • Type D meeting with FDA ✓ • EMA Scientific Advice • Initiate Phase 3 trial • Spanish Government Public- potential pivotal trial design potential pivotal trial design if regulat
Slide 18: VCN-01 in Head & Neck Cancer
@ Theriva VCN-01 IN HEAD & NECK CANCER
Slide 19: VCN-01 IV + Anti-PD-L1 Phase 1 Trial in HNSCC
VCN-01 IV + ANTI-PD-L1 PHASE 1 TRIAL in HNSCC Multicenter, open-label, dose escalation study (NCT03799744) ✓ Single IV doses of VCN-01 combined with anti-PD-L1 ✓ Patients with metastatic squamous cell carcinoma of the head & neck previously REFRACTORY to anti-PD(L)1 treatment (R/M HNSCC) ✓ Evaluate
Slide 20: Extended Survival with VCN-01 + Durvalumab
EXTENDED SURVIVAL with VCN-01+DURVALUMAB Survival correlated with PD-L1 upregulation after VCN-01 treatment • Higher than expected survival (OS) Overall Survival vs CPS in Biopsies at Day 8 despite previous anti-PD(L)1 failure Spearman r = 0.7676 P (2-tailed) = 0.0050 Regimen Median OS (95% CI), mos
Slide 21: VCN-01 Findings in R/M HNSCC
VCN-01 FINDINGS in R/M HNSCC Data support VCN-01 MOA and immune enhancing effects • VCN-01 has an acceptable adverse event profile when administered prior to durvalumab (Imfinzi®) • VCN-01 reaches tumors, has sustained replication and PH20 expression • VCN-01 treatment led to downregulation of tumor
Slide 22: VCN-01 in Retinoblastoma
@ Theriva VCN-01 IN RETINOBLASTOMA
Slide 23: Retinoblastoma, a Rare Pediatric Malignancy
RETINOBLASTOMA, A RARE PEDIATRIC MALIGNANCY • Retinoblastoma (Rb) is an orphan indication that accounts for ~2-3% of all childhood cancers¹ • 200-300 cases each year in the USA, EU²-⁴ • VCN-01 selectivity enables development as an intravitreal treatment for Rb patients • VCN-01 could be used in comb
Slide 24: VCN-01 in Retinoblastoma
VCN-01 IN RETINOBLASTOMA • Single center, open-label, dose escalation study of intravitreal (IVit) VCN-01¹-³ Promising Results in Patients Treated • Children aged 1-12 years (n=9) with High Dose VCN-01 • Retinoblastoma that is recurrent or refractory to chemotherapy Reduced number and size of tumor
Slide 25: Interim Adverse Event Data for Intravitreal VCN-01
INTERIM ADVERSE EVENT DATA FOR INTRAVITREAL VCN-01 Two Intravitreal VCN-01 Doses of 2.0x10⁹ or 2.0x1010 vp per eye¹ Adverse Reaction Pts All Grades Grade ≥3 Stable Electroretinographic Signals CTCAE grade N n % n % Uveitis 6 2 33% 2 33% Eye oedema 6 1 17% 0 0% Conjunctival hyperemia 6 1 17% 0 0% Eye
Slide 26: VCN-01 Development in Retinoblastoma
VCN-01 DEVELOPMENT IN RETINOBLASTOMA • Phase 1 ISS Completed H1 2024 • Initial data demonstrate acceptable adverse event profile and one durable complete response • Developing a clinical protocol for an open-label, multinational study • Retinoblastoma patients with vitreous seeds • IVit VCN-01 in co
Slide 27: VCN-X Next Generation OV Discovery Platform
VCN-X NEXT GENERATION OV DISCOVERY PLATFORM
Slide 28: Albumin Shield to Enhance OV Systemic Delivery
ALBUMIN SHIELD™ to ENHANCE OV SYSTEMIC DELIVERY • Albumin Shield technology protects OVs as they OV Parent oncolytic virus (OV) susceptible to neutralizing travel to tumors after systemic administration¹,² antibodies • Albumin Shield modified OVs bind albumin in the patient’s blood to form a protect
Slide 29: Theriva OV Pipeline Discovery and Development
THERIVA OV PIPELINE DISCOVERY AND DEVELOPMENT Advancing founders’ decade of world leading OV innovation Common Features Product Specific Features Clinically-tested Adenovirus Expressing PH20 VCN-11 Hyaluronidase alone Hyaluronidase to Degrade Stroma + VCN-12 Hyaluronidase + Toxins Albumin Shield™ To
Slide 30: Appendices
@ Theriva APPENDICES
Slide 31: Intellectual Property
INTELLECTUAL PROPERTY Hyaluronidase OV Albumin Shield™ Oral β-Lactamase Oral IAP VCN-01, VCN-11 VCN-11, Discovery SYN-004, -006, -007 SYN-020 Composition of Matter Composition of Matter Composition of Matter Manufacturing Know-how (exp 2030) (exp 2034) (exp 2031-5) (Trade Secret) Methods of Use and
Slide 32: VCN-01 in Pancreatic Cancer
@ Theriva VCN-01 IN PANCREATIC CANCER
Slide 33: VCN Oncolytic Virus Genetic Modifications
VCN ONCOLYTIC VIRUS GENETIC MODIFICATIONS Fiber Shaft KKTK Ad5 ABD albumin binding domain LITR E1a MLP L1 L2 L3 L4 L5 RITR (streptococcal protein G)¹ wild type | | Ad5 Adenovirus type 5 Enables replication in normal cells Facilitates liver sequestration E1a-Δ24 deletion of 24 base pairs within the E
Slide 34: Extensive VCN-01 Phase 1 Clinical Experience
EXTENSIVE VCN-01 PHASE 1 CLINICAL EXPERIENCE 89 Patients Treated in Diverse Cancer Indications Phas Rout Location Indication Co-therapy Status Registry e e Multicenter (ESP) 1 Part I: None Part I: Solid tumor Parts II,III: Gemcitabine + IV Complete¹ NCT02045602 Part II, III: PDAC nab-Paclitaxel Gemc
Slide 35: Most Common IV VCN-01 Related AEs
MOST COMMON IV VCN-01 RELATED AEs [NCT02045602] ADVERSE EVENTS¹ Part I (Alone, n=16) Part II (Concomitant, 12)² Part III (Sequential, 14)³ Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3* Grade 1-2 Grade ≥3 Febrile neutropenia - - - 2 (16.7%) - - Neutropenia/Neutrophil count decreased 2 (12.5%) - 1 ( 8.3%) 1
Slide 36: Expansion Opportunities for VCN-01 in PDAC
EXPANSION OPPORTUNITIES for VCN-01 in PDAC Alternate treatment lines and new chemotherapy combinations Borderline Locally Advanced Metastatic / Recurrent Status Resectable Resectable (unresectable) (unresectable) Staging Stage I Stage II Stage III Stage IV Radiotherapy if increases resection margins
Slide 37: VCN-01 with Gemcitabine/Nab Paclitaxel
VCN-01 WITH GEMCITABINE/ NAB PACLITAXEL Potential survival benefit compared to all first-line chemotherapy COMPANY THERIVA BIOLOGICS (Phase 1) PDAC FIRST LINE CHEMOTHERAPY Virus VCN-01 VCN-01 .. .. .. 3.3x1012 vp x1 Dose 1x1013 vp x 1* .. .. .. .. 1x1013 vp x 1* Chemotherapy Gemcitabine + Gemcitabin
Slide 38: Theriva Oncolytic Viruses Key Publications
THERIVA ONCOLYTIC VIRUSES KEY PUBLICATIONS Bayo-Puxan N et al. (2006) Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob- mediated retargeting. J Gen Virol 87:2487–2495 Bazan-Peregrino M et al. (2021) VCN-01 disrupts
Slide 39: Pancreatic Cancer References
PANCREATIC CANCER REFERENCES DESCRIPTION, CLASSIFICATION, STAGING, STROMA Balachandran VP et al. (2019) Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156:2056-72 Christenson ES et al. (2020) Current and emerging therapies for patients wit
Slide 40: Retinoblastoma (Rb) References
RETINOBLASTOMA (Rb) REFERENCES DESCRIPTION, CLASSIFICATION, STAGING American Academy of Ophthalmology. EyeWiki®. Retinoblastoma. https://eyewiki.org/Retinoblastoma American Cancer Society. Key statistics for retinoblastoma. https://www.cancer.org/cancer/retinoblastoma/about/key-statistics.html Cantu
Slide 41: OV Company References
OV COMPANY REFERENCES CG Oncology CG0070 (cretostimogene grenadenorepvec) https://cgoncology.com Ramesh N et al. (2006) CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 12:305 Svatek R
Slide 42: OV Company References
OV COMPANY REFERENCES Oncolytics Biotech: Pelareorep (formerly Reolysin®) https://oncolyticsbiotech.com Arnold D et al. Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Results from the GOBLET study
Theriva Biologics — Investor Presentation (December 2024) on 6ix